This was designed for solid tumors. But they found an adverse event in lowered PLT count
It is specific to this effect and for MPNs this bug is a feature. They made the connection:
"the on-target dose/exposure-proportional decrease in platelet constitute a proof-of-principle that JBI-802 can be an active compound in hematological malignancies like Essential Thrombocythemia (ET)". They are planning trials.
There is a need for a PLT specific agent, Bomedemstat in its long trials is the only other new one.
It will be interesting whether it has any influence on the mutation.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.